Skip to main content
. 2012 Jun 1;26(11):1247–1262. doi: 10.1101/gad.193565.112

Figure 5.

Figure 5.

Genetic or pharmacological targeting of PDGFRβ decreases tumorsphere formation. In vitro limiting dilution assay with 08-387 (A) and 4121 (B) demonstrated that higher PDGFRβ expression led to increasing tumorsphere formation when CD133 was used as a GSC marker. In vitro limiting dilution assays with 08-387 (C) and 08-322 (D) GSCs expressing nontargeting shRNA (shNT) or two different shRNAs directed against shPDGFRβ (shPDGFRβ I and shPDGFRβ II) demonstrated that tumorsphere formation decreases with shPDGFRβ. The tumorsphere formation capacity of 08-387 (E) and 08-322 (F) GSCs is decreased with PDGFRβ Inhibitor III treatment in the in vitro limiting dilution assay. Limiting dilution analyses were performed using Extreme Limiting Dilution Analysis (http://bioinf.wehi.edu.au/software/elda). (*) P < 0.0001.